AI assistant
C4 Therapeutics, Inc. — Director's Dealing 2021
Aug 3, 2021
33861_dirs_2021-08-02_f0530899-f6cb-4d35-8b0d-547182c5fbb4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-07-29
Reporting Person: Fisher Stewart (Chief Scientific Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-07-29 | Common Stock | S | 50211 | $45.0027 | Disposed | 57905 | Direct |
| 2021-08-02 | Common Stock | S | 18104 | $45.0042 | Disposed | 39801 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.085. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.